Overview - Bayer Investor Relations

Create Value for our

Shareholders

We want to create value for our shareholders through innovation, growth and high earning power.

Investor News

February 15, 2019

Not intended for U.S. and UK Media

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)

February 14, 2019

Not intended for U.S. and UK Media - American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019

Bayer's darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

News Overview

February 27, 2019

Investor Conference Call

Publication of FY/Q4 2018 Results

CONSENSUS

Q4 2018 Consensus Estimates

The company is covered by various German and international financial analysts.

Read Consensus

December 05, 2018 // London

Capital Markets Day 2018

MEHR

Services

Tailored to your interest

Key Messages

Read Key Messages to Investors

Current Event

February 26, 2019

Announcement of proposed dividend

Overview

Latest Reports and Handout

Interim Report Third Quarter 2018 Annual Report 2017 Investor Handout

INVESTOR CONFERENCE CALL

Q3 2018 Investor Conference Call

Q3 results have been published on November 13, 2018.

INTERIM REPORT

Interim Report Q3 2018

On November 13, 2018, our Interim Report Third Quarter 2018 has been published.

Enough Food for Everyone?

The Future of Agriculture and Food

Last updated: February 21, 2019